Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25900282 | 0.86 | OGA (0.76) | OGA | |
| SCHEMBL17551228 | 0.80 | OGA (1.00) | OGA | |
| SCHEMBL19461163 | 0.80 | OGA (1.00) | OGA | |
| SCHEMBL19473612 | 0.80 | OGA (1.00) | OGA | |
| SCHEMBL17551230 | 0.80 | OGA (1.00) | OGA | |
| SCHEMBL25898586 | 0.77 | OGA (0.62) | OGA | |
| SCHEMBL19295787 | 0.75 | OGA (0.72) | OGA | |
| SCHEMBL20759335 | 0.75 | OGA (1.00) | OGA | |
| SCHEMBL19283894 | 0.75 | OGA (1.00) | OGA | |
| SCHEMBL23565458 | 0.74 | OGA (0.70) | OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419972-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2023-07-26 | — | — | EP | disclosed |
| US-11612599-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2023-03-28 | — | — | US | disclosed |
| EP-3419971-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-04-20 | — | — | EP | disclosed |
| EP-3419971-B1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2022-04-20 | — | — | EP | disclosed |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-06-24 | — | — | US | disclosed |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2021-06-24 | — | — | US | disclosed |
| US-10556902-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2020-02-11 | — | — | US | disclosed |
| US-10556902-B2 | Glycosidase inhibitors | ASCENEURON SA (CH) | 2020-02-11 | — | — | US | disclosed |
| US-20190055239-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2019-02-21 | — | — | US | disclosed |
| US-20190055239-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON SA (CH) | 2019-02-21 | — | — | US | disclosed |
| WO-2017144639-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144633-A1 | GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11612599-B2 | Glycosidase inhibitors | ENGASE, GAA, GLA | OGA 73/4885 |
| US-10556902-B2 | Glycosidase inhibitors | ENGASE, GAA, GLA | OGA 69/4885 |
| US-20210186958-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | OGA 73/4885 |
| US-20190055239-A1 | GLYCOSIDASE INHIBITORS | ENGASE, GAA, GLA | OGA 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.